Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphadenopathy 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Adenoviridae Infections 1Adenocarcinoma 1

Interventions

spartalizumab 2pembrolizumab 2trastuzumab deruxtecan 1trametinib 1siremadlin 1sargramostim 1resiquimod 1poly ICLC 1pegfilgrastim 1nazartinib 1liposomal doxorubicin 1lenvatinib 1eribulin 1enzalutamide 1canakinumab 1Vaccines 1TKM-080301 1Quality of Life 1Prednisone 1Prednisolone 1Patient Reported Outcome Measures 1Panobinostat 1Molecular Diagnostic Techniques 1MORAb-202 1LCL161 1Ipilimumab 1Immunotherapy 1Imatinib Mesylate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Vaccines × Breast × Clear all
NCT01730118 2022-09-10

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
33 enrolled 18 charts
Breast

Adenocarcinoma, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡